22 completed, 7 unknown, 3 recruiting, 2 active not recruiting. 17 Not applicable, 8 Phase 3, 6 Phase 2, 3 Phase 1, 2 Phase 4.
Follow Glaucoma, Neovascular: new trials by email Literature Review of Glaucoma, Neovascular trials Research Report on Glaucoma, Neovascular
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Observation of Iris Blood Flow Via OCTA in Diabetic Neovascular Glaucoma Neovascular Glaucoma, Type 2 Diabetes | Recruiting | Qilu Hospital of Shandong University | 98 | 2026-05-23 | 2026-07-28 | |
| Minimally Invasive Suprachoroidal Drainage for the Treatment of Neovascular Glaucoma minimally invasive suprachoroidal drainage - Neovascular Glaucoma | Not applicable | Active not recruiting | Zhongnan Hospital | 30 | 2025-01-01 | 2025-10-01 |
| Efficacy and Safety of Minimally Invasive Suprachoroidal Drainage Neovascular Glaucoma | Completed | Zhongnan Hospital | 50 | 2024-07-01 | 2026-10-20 | |
| Effect of Subconjunctival 5-fluorouracil on the Outcome of Ahmed Valve in Neovascular Glaucoma AGV with intraoperation MMC and postoperative BSS, AGV with intraoperation MMC and post operation 5FU - Neovascular Glaucoma | Not applicable | Unknown | Iran University of Medical Sciences | 70 | 2024-05-01 | 2025-05-06 |
| MicroPulse TLT - UK Study Micropulse Transscleral laser therapy - Glaucoma, Glaucoma Eye | Unknown | Imperial College Healthcare NHS Trust | 250 | 2023-05-01 | 2023-03-28 | |
| A Study on the Treatment Strategy of NVG Secondary to PDR anti-VEGF - Neovascular Glaucoma, Proliferative Diabetic Retinopathy | Not applicable | Completed | Ruijin Hospital | 39 | 2021-12-12 | 2023-08-21 |
| KDR2-2 Suspension Eyedrop in the Treatment of Neovascular Glaucoma (KDR-NVG) Trial 4mg/ml KDR2-2 suspension eyedrop, 16mg/ml KDR2-2 suspension eyedrop - Neovascular Glaucoma, Neovascularization | Phase 1 | Active not recruiting | Sun Yat-sen University | 40 | 2021-04-19 | 2024-12-11 |
| Study to Learn More About Safety of Aflibercept Injection in Japanese Patients With Neovascular Glaucoma (NVG) Aflibercept (Eylea, BAY86-5321) - Neovascular Glaucoma | Recruiting | Bayer | 480 | 2020-11-27 | 2026-06-30 | |
| INTEGRAL Study: A Longitudinal Study of Surgeries and Lasers in Glaucoma: Long-term Results and Success Predictors Analysed From a Large-scale Retrospective and Prospective Glaucoma Register Glaucoma Open-Angle, Glaucoma Eye | Enrolling by invitation | Dr. Kaweh Mansouri | 30000 | 2019-01-15 | 2022-05-05 | |
| Aflibercept as Adjunctive Treatment for Filtration Surgery in Neovascular Glaucoma Aflibercept Ophthalmic - Intraocular Pressure, Neovascular Glaucoma | Not applicable | Completed | Siriraj Hospital | 5 | 2018-11-01 | 2021-07-21 |
| Study to Learn How the Drug Aflibercept Works in in Japanese Patients With Increased Eye Pressure That is Caused by New Blood Vessels Growing in the Eye (Neovascular Glaucoma or NVG). Safety of the Drug and Patients' Tolerability of the Drug Injection is Also Studied Aflibercept (EYLEA, BAY86-5321), Topical IOP-lowering drugs - Glaucoma, Neovascular | Phase 3 | Completed | Bayer | 16 | 2018-10-03 | 2020-03-03 |
| Intracameral Versus Intravitreal Bevacizumab Injection in NVG: RCT Intracameral injection, Intravitreal injection - Glaucoma, Neovascular, Vascular Endothelial Growth Factor Overexpression | Not applicable | Recruiting | Prince of Songkla University | 40 | 2018-08-01 | 2025-08-21 |
| Clinical Characteristics of Neovascular Glaucoma Neovascular Glaucoma | Completed | Zhongnan Hospital | 400 | 2018-01-01 | 2025-09-17 | |
| Treatment Outcomes of MicroPulse Trans-scleral Cyclophotocoagulation in Uncontrolled Glaucoma MicroPulse® P3 Glaucoma Device (MP3) - Glaucoma, Glaucoma, Open-Angle | Not applicable | Completed | Centre hospitalier de l'Université de Montréal (CHUM) | 52 | 2017-06-19 | 2021-10-08 |
| The Effect of Conbercept Injection Through Different Routes for Neovascular Glaucoma Intracameral injection, Intravitreal injection - Neovascular Glaucoma | Not applicable | Completed | Second Affiliated Hospital of Xi'an Jiaotong University | 30 | 2017-04-01 | 2018-05-23 |
| Trial of Aganirsen in iCRVO Patients at Risk of Developing NVG aganirsen - Ischaemic Central Retinal Vein Occlusion, Neovascular Glaucoma | Phase 2 / Phase 3 | Unknown | Gene Signal SAS | 333 | 2017-01-01 | 2016-10-31 |
| Intravitreal Ranibizumab (Lucentis®) for Neovascular Glaucoma- a Randomized Controlled Study Intravitreal ranibizumab - Glaucoma, Neovascular, Ranibizumab | Phase 3 | Unknown | LEANDRO CABRAL ZACHARIAS | 28 | 2016-10-01 | 2016-09-27 |
| Ahmed Glaucoma Valve Surgery With Mitomycin-C Mitomycin-C, Balanced Salt Solution, Ahmed Glaucoma Valve Implant - Glaucoma, Primary Open Angle Glaucoma | Phase 2 | Completed | University of California, San Francisco | 119 | 2016-06-01 | 2022-05-31 |
| Analysis of Aqueous and Vitreous Humor Ranibizumab, No Ranibizumab - Proliferative Diabetic Retinopathy, Macular Degeneration | Phase 2 | Unknown | California Retina Consultants | 45 | 2015-07-01 | 2017-03-01 |
| Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients Aflibercept (Eylea, BAY 86-5321), Sham Injection - Glaucoma, Neovascular | Phase 3 | Completed | Bayer | 54 | 2015-04-02 | 2017-09-15 |
Showing 20 of 39. Sign in to see all of them.
Glaucoma (10) · Glaucoma, Open-Angle (10) · Glaucoma, Angle-Closure (7) · Diabetic Retinopathy (5) · Retinal Vein Occlusion (4) · Exfoliation Syndrome (3) · Macular Edema (2) · Carotid Stenosis (1) · Choroidal Neovascularization (1) · Diabetes Mellitus, Type 2 (1) · Hydrophthalmos (1) · Macular Degeneration (1) · Neovascularization, Pathologic (1) · Ocular Hypertension (1)
Eye Diseases (39) · Ocular Hypertension (38) · Glaucoma (29) · Retinal Diseases (9) · Cardiovascular Diseases (7) · Vascular Diseases (7) · Diabetes Complications (5) · Diabetes Mellitus (5) · Diabetic Angiopathies (5) · Endocrine System Diseases (5) · Uveal Diseases (5) · Embolism and Thrombosis (4) · Thrombosis (4) · Venous Thrombosis (4) · Iris Diseases (3)
Ranibizumab (8) · aflibercept (4) · Trabeculectomy (3) · Hanks Balanced Salt Solution (2) · Intracameral Injection (2) · Intravitreal Injections (2) · Bevacizumab (1) · Epinephrine (1) · GS 101 (1) · Mitomycin (1) · Travoprost (1) · Triamcinolone (1) · Tutoplast (1) · salicylhydroxamic acid (1)
Bayer (3) · Zhongnan Hospital (3) · Ain Shams University (2) · Federal University of São Paulo (2) · Prince of Songkla University (2) · Ruijin Hospital (2) · Siriraj Hospital (2) · Wills Eye (2) · Asociación para Evitar la Ceguera en México (1) · Cairo University (1) · California Retina Consultants (1) · Centre hospitalier de l'Université de Montréal (CHUM) (1) · Dr. Kaweh Mansouri (1) · Gene Signal SAS (1) · Imperial College Healthcare NHS Trust (1)
China (8) · United States (7) · Thailand (4) · Japan (3) · Brazil (2) · Iran (2) · Canada (1) · Egypt (1) · Estonia (1) · France (1) · Germany (1) · India (1) · Mexico (1) · Switzerland (1)
Assoc.Prof.Weerawat Kiddee, MD (1) · Augusto Paranhos Jr, PHD (1) · Felix Gil-Carrasco, MD (1) · Harmanjit Singh, MD (1) · Ivana Kim, M.D. (1) · Kuldar Kaljurand, MD (1) · Ling Bai, MD,PhD (1) · Luiz A Melo Jr, MD (1) · Malik Y Kahook, MD (1) · Marlene M Moster, MD (1) · Marlene R Moster, MD (1) · Michael Marchand, MD (1) · Michael P Blair, MD (1) · Mostafa A EL-Helw, M.D. (1)
PMID 37010901, PMID 18173426, PMID 18425438, PMID 23893090, PMID 24794283, PMID 25580888, PMID 25812531, PMID 27293875, PMID 28302155, PMID 32021066, PMID 32184556, PMID 32765127, PMID 32890108, PMID 33330958, PMID 33330959, PMID 33577756, PMID 35083234, PMID 36912740, PMID 40826269
2014 (1)